Pharmaceutical patent bargains: the Brazilian experience

In the backdrop of the strict patent regime flatly adopted by the World Trade Organization (WTO) for all countries, a few countries constantly challenge this system through aggressive patent bargains. Within the pharmaceutical sector, noticeably, some countries now threaten to issue or otherwise actually issue compulsory licenses that may sway large pharmaceutical companies into selling drugs with large discounts or into granting voluntary licenses domestically. That is conspicuously the negotiation strategy adopted by Brazil in its negotiations with big international pharmaceutical companies.This paper explains Brazil’s aggressive bargaining approach based on an analysis of two aspects of its political economy. The first has to do with the international context of patent bargaining in the post-WTO era. Accordingly, the existence of large and fast growing domestic markets position countries such as Brazil as strategic destinations for Foreign Direct Investment (FDI) and trade. Together with an absence of a propensity to innovate in pharmaceutical products, these conditions boost Brazil’s bargaining power for issuing compulsory licenses over pharmaceutical products. The second aspect is related to political economy dynamics inside Brazil. Accordingly, the political framework in Brazil undermines long-term policies and favors short-sighted ones also vis-a-vis R&D investments in the pharmaceutical industry. This remains true regardless of the strictness of the patent regime in place. The lesson of Brazil is relevant arguably for other more powerful developing countries which presently examine Brazil's approach while further challenging the WTO's strict patent policy for the future.

Relação matriz-subsidiária de multinacional farmacêutica: fatores determinantes na decisão estratégica

Este trabalho tem como principal objetivo analisar a relação matriz-subsidiária de uma empresa do setor farmacêutico no Brasil. Para atender ao objetivo deste trabalho, foi realizada uma revisão da literatura sobre o tema na área de negócios internacionais, cadeia de suprimentos, custos logísticos, aparato regulatório, infra-estrutura e estratégia corporativa, a fim de compreender os diferentes fatores que influenciam os papéis desempenhados pelas subsidiárias com relação às matrizes e aos mercados em que se encontram instaladas. A partir deste referencial teórico, foram selecionadas algumas tipologias como critérios de análise para a investigação empírica das práticas na empresa selecionada. A metodologia utilizada engloba um estudo de caso único com duas sub unidades de análise, a subsidiária e a matriz. Também foram realizadas análises do setor farmacêutico internacional e nacional (inclusive o modelo regulatório), visando melhor compreensão e contextualização da relação matriz-subsidiária. A análise dos resultados deste estudo de caso, fundamentados no referencial teórico conclui que esta subsidiária está sujeita a fortes impactos do aparato regulatório por parte da Anvisa e da falta de infra-estrutura logística para maior eficiência e competitividade perante seus concorrentes, o que determina a baixa autonomia perante a matriz quanto ao processo decisório estratégico dentro da corporação.

Coordination in brazilian pharmaceutical supply chains

Supply chain coordination (SCC) can be a challenge for many organizations as different firms in the same chain has different expectations and interdependencies (Arshinder & Deshmukh, 2008). Lack of SCC can result in the bullwhip effect and poor performance for a firm and its partners. By investigating the phenomenon in the Brazilian pharmaceutical supply chain using a qualitative research, this paper aims to understand the main issues that avoid a better integrated chain. Results of 21 interviews suggested that the lack of coordination in this environment was influenced by the network design and the history of the sector in Brazil, as well as scarce resources